Related Experiment Video
Updated: Mar 19, 2026
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to
Catherine J Drummond1, Arman Esfandiari1, Junfeng Liu1
1Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.
Abstract:
Non-genotoxic reactivation of the p53 pathway by MDM2-p53 binding antagonists is an attractive treatment strategy for wild-type TP53 cancers. To determine how resistance to MDM2/p53 binding antagonists might develop, SJSA-1 and NGP cells were exposed to growth inhibitory concentrations of chemically distinct MDM2 inhibitors, Nutlin-3 and MI-63, and clonal resistant cell lines generated. The p53 mediated responses of parental and resistant cell lines were compared. In contrast to the parental cell lines, p53 activation by Nutlin-3, MI-63 or ionizing radiation was not observed in either the SJSA-1 or the NGP derived cell lines. An identical TP53 mutation was subsequently identified in both of the SJSA-1 resistant lines, whilst one out of three identified mutations was common to both NGP derived lines. Mutation specific PCR revealed these mutations were present in parental SJSA-1 and NGP cell populations at a low frequency. Despite cross-resistance to a broad panel of MDM2/p53 binding antagonists, these MDM2-amplified and TP53 mutant cell lines remained sensitive to ionizing radiation (IR). These results indicate that MDM2/p53 binding antagonists will select for p53 mutations present in tumours at a low frequency at diagnosis, leading to resistance, but such tumours may nevertheless remain responsive to alternative therapies, including IR.
Insights
MDM2 inhibitors can lead to drug resistance by selecting for TP53 mutations in cancer cells. However, these resistant cells may still respond to other treatments like ionizing radiation (IR).
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Reactivating the p53 pathway via MDM2-p53 binding antagonists is a promising cancer treatment strategy.
- Understanding resistance mechanisms to MDM2 inhibitors is crucial for effective therapeutic development.
Purpose of the Study:
- To investigate how resistance to MDM2/p53 binding antagonists develops in cancer cells.
- To compare the p53-mediated responses of parental and resistant cell lines to MDM2 inhibitors and ionizing radiation.
Main Methods:
- SJSA-1 and NGP cells were treated with MDM2 inhibitors (Nutlin-3, MI-63) to generate resistant cell lines.
- p53 pathway activation was assessed in parental and resistant cells following drug or ionizing radiation (IR) treatment.
- TP53 mutations in resistant cell lines were identified and their presence in parental populations analyzed using mutation-specific PCR.
Main Results:
- Resistant cell lines (SJSA-1, NGP) showed no p53 activation in response to MDM2 inhibitors or IR.
- Identical TP53 mutations were found in SJSA-1 resistant lines, and common mutations in NGP resistant lines.
- These TP53 mutations were present at low frequencies in the parental cell populations.
- Despite cross-resistance to MDM2/p53 antagonists, resistant cells remained sensitive to IR.
Conclusions:
- MDM2/p53 binding antagonists can select for pre-existing low-frequency TP53 mutations, leading to treatment resistance.
- Cancer cells with MDM2-amplified and TP53 mutant status may remain responsive to alternative therapies like IR.
Related Concept Videos
02:23Abnormal Proliferation
02:56Treatment Resistant Cancers
02:36DNA Damage can Stall the Cell Cycle
02:36DNA Damage Can Stall the Cell Cycle
01:18Other Unique Bacteria
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...